The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management
Open accessAbstract
Diabetic nephropathy (DN) has been recognized as a severe complication of diabetes mellitus and a dominant pathogeny of end-stage kidney disease, which causes serious health problems and great financial burden to human society worldwide. Conventional strategies, such as renin-angiotensin-aldosterone system blockade, blood glucose level control, and bodyweight reduction, may not achieve satisfactory outcomes in many clinical practices for DN management. Notably, due to the multi-target function, Chinese medicine possesses promising clinical benefits as primary or alternative therapies for DN treatment. Increasing studies have emphasized identifying bioactive compounds and molecular mechanisms of reno-protective effects of Chinese medicines. Signaling pathways involved in glucose/lipid metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection have been identified as crucial mechanisms of action. Herein, we summarize the clinical efficacies of Chinese medicines and their bioactive components in treating and managing DN after reviewing the results demonstrated in clinical trials, systematic reviews, and meta-analyses, with a thorough discussion on the relative underlying mechanisms and molecular targets reported in animal and cellular experiments. We aim to provide comprehensive insights into the protective effects of Chinese medicines against DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Temporal trends in the prevalence of diabetic kidney disease in the United States
de Boer, I. H. (2011) · JAMA · doi:10.1001/jama.2011.861 · Cited by 1,036
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M., & Natarajan, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 600
Proteinuria in diabetic kidney disease: A mechanistic viewpoint
Jefferson, J. A., Shankland, S. J., & Pichler, R. H. (2008) · Kidney International · doi:10.1038/ki.2008.128 · Cited by 419
Diagnosis and Management of Type 2 Diabetic Kidney Disease
Doshi, S. M., & Friedman, A. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11111016 · Cited by 344
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
Physiological Regulation of Prostaglandins in the Kidney
Hao, C.-M., & Breyer, M. D. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100614 · Cited by 247
Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway
Zhu, L., Han, J., Yuan, R., Xue, L., & Pang, W. (2018) · Biological Research · doi:10.1186/s40659-018-0157-8 · Cited by 208
Cited by
The sirtuin family in health and disease
Wu, Q.-J., Zhang, T.-N., Chen, H.-H., Yu, X.-F., Lv, J.-L., Liu, Y.-Y., Liu, Y.-S., Zheng, G., Zhao, J.-Q., Wei, Y.-F., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01257-8 · Cited by 862
Self-citation
Metadata
- Authors
- Tang, G., Li, S., Zhang, C., Chen, H., Wang, N., & Feng, Y.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 11
- Issue
- 9
- Pages
- 2749-2767
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3127843453
- Cited by
- 364
- References
- 111
- FWCI
- 29.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.